Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease

Active:	Yes
Cancer Type:	Graft Versus Host Disease	NCT ID:	NCT06046248
Trial Phases:	Phase II	Protocol IDs:	NSH 1385 (primary)
Eligibility:	18 Years and older (Adult, Older Adult ), Male and Female	Study Type:	Treatment
Study Sponsor:	Northside Hospital, Inc.
NCI Full Details:	https://clinicaltrials.gov/study/NCT06046248

Summary

This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.